224 related articles for article (PubMed ID: 26023321)
1. Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation.
Nakamura N; Matsui T; Ishibashi Y; Yamagishi S
Diabetol Metab Syndr; 2015; 7():48. PubMed ID: 26023321
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis.
Maeda S; Matsui T; Takeuchi M; Yamagishi S
Diabetes Metab Res Rev; 2013 Jul; 29(5):406-12. PubMed ID: 23508966
[TBL] [Abstract][Full Text] [Related]
3. Tofogliflozin, A Highly Selective Inhibitor of SGLT2 Blocks Proinflammatory and Proapoptotic Effects of Glucose Overload on Proximal Tubular Cells Partly by Suppressing Oxidative Stress Generation.
Ishibashi Y; Matsui T; Yamagishi S
Horm Metab Res; 2016 Mar; 48(3):191-5. PubMed ID: 26158396
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
Ojima A; Matsui T; Nishino Y; Nakamura N; Yamagishi S
Horm Metab Res; 2015 Aug; 47(9):686-92. PubMed ID: 25611208
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice.
Hatanaka T; Ogawa D; Tachibana H; Eguchi J; Inoue T; Yamada H; Takei K; Makino H; Wada J
Pharmacol Res Perspect; 2016 Aug; 4(4):e00239. PubMed ID: 28116093
[TBL] [Abstract][Full Text] [Related]
6. Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent.
Nomura S
Curr Top Med Chem; 2010; 10(4):411-8. PubMed ID: 20180760
[TBL] [Abstract][Full Text] [Related]
7. Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.
Chichger H; Cleasby ME; Srai SK; Unwin RJ; Debnam ES; Marks J
Exp Physiol; 2016 Jun; 101(6):731-42. PubMed ID: 27164183
[TBL] [Abstract][Full Text] [Related]
8. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
Vallon V; Thomson SC
Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
[TBL] [Abstract][Full Text] [Related]
9. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
Gallo LA; Wright EM; Vallon V
Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
[TBL] [Abstract][Full Text] [Related]
10. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption.
Li S; Wang N; Guo X; Li J; Zhang T; Ren G; Li D
Biomed Pharmacother; 2018 Dec; 108():355-366. PubMed ID: 30227329
[TBL] [Abstract][Full Text] [Related]
12. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
[TBL] [Abstract][Full Text] [Related]
13. Protective Role of Sodium-Glucose Co-Transporter 2 Inhibition Against Vascular Complications in Diabetes.
Yamagishi S; Matsui T
Rejuvenation Res; 2016 Apr; 19(2):107-14. PubMed ID: 26228073
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells.
Yamagishi S; Inagaki Y; Okamoto T; Amano S; Koga K; Takeuchi M
Kidney Int; 2003 Feb; 63(2):464-73. PubMed ID: 12631112
[TBL] [Abstract][Full Text] [Related]
15. Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression.
Ishibashi Y; Matsui T; Takeuchi M; Yamagishi S
Horm Metab Res; 2012 Nov; 44(12):891-5. PubMed ID: 22864903
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic and renal implications of sodium-glucose cotransporter- 2 inhibitors in type 2 diabetes mellitus.
Tejedor Jorge A
Med Clin (Barc); 2016 Nov; 147 Suppl 1():35-43. PubMed ID: 28760224
[TBL] [Abstract][Full Text] [Related]
17. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
[TBL] [Abstract][Full Text] [Related]
18. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.
Rahmoune H; Thompson PW; Ward JM; Smith CD; Hong G; Brown J
Diabetes; 2005 Dec; 54(12):3427-34. PubMed ID: 16306358
[TBL] [Abstract][Full Text] [Related]
19. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
[TBL] [Abstract][Full Text] [Related]
20. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
Ohgaki R; Wei L; Yamada K; Hara T; Kuriyama C; Okuda S; Ueta K; Shiotani M; Nagamori S; Kanai Y
J Pharmacol Exp Ther; 2016 Jul; 358(1):94-102. PubMed ID: 27189972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
